Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions

Rezonja, Renata; Knez, Lea; Cufer, Tanja; Mrhar, Aleš
January 2013
Radiology & Oncology;2013, Vol. 47 Issue 1, p1
Academic Journal
Background. Etoposide is a chemotherapeutic agent, widely used for the treatment of various malignancies, including small cell lung cancer (SCLC), an aggressive disease with poor prognosis. Oral etoposide administration exhibits advantages for the quality of life of the patient as well as economic benefits. However, widespread use of oral etoposide is limited by incomplete and variable bioavailability. Variability in bioavailability was observed both within and between patients. This suggests that some patients may experience suboptimal tumor cytotoxicity, whereas other patients may be at risk for excess toxicity. Conclusions. The article highlights dilemmas as well as solutions regarding oral treatment with etoposide by presenting and analyzing relevant literature data. Numerous studies have shown that bioavailability of etoposide is influenced by genetic, physiological and environmental factors. Several strategies were explored to improve bioavailability and to reduce pharmacokinetic variability of oral etoposide, including desired and undesired drug interactions ( e.g. with ketoconazole), development of suitable drug delivery systems, use of more water-soluble prodrug of etoposide, and influence on gastric emptying. In addition to genotype-based dose administration, etoposide is suitable for pharmacokinetically guided dosing, which enables dose adjustments in individual patient. Further, it is established that oral and intravenous schedules of etoposide in SCLC patients do not result in significant differences in treatment outcome, while results of toxicity are inconclusive. To conclude, the main message of the article is that better prediction of the pharmacokinetics of oral etoposide may encourage its wider use in routine clinical practice.


Related Articles

  • A Randomized Controlled Study of Chemotherapy: Etoposide Combined with Oxaliplatin or Cisplatin Regimens in the Treatment of Extensive-stage Small Cell Lung Cancer in Elderly Patients. Dan Pu; Mei Hou; Zhixi Li; Xiaomei Zeng // Chinese Journal of Lung Cancer;Jan2013, Vol. 16 Issue 1, p20 

    Background and objective Etoposide combined cisplatin (EP) is the most commonly-used first-line treatment combination chemotherapy regimen in the treatment of extensive-stage small cell lung cancer (SCLC), The sideeffects of cisplatin, such as nausea and vomiting, influence patients' quality of...

  • Leveraging Genetically Engineered Mouse Models of Small Cell Lung Cancer for Advanced Therapeutic Studies. FARAGO, ANNA // Oncologist;Oct2013 Supplement 1, Vol. 18, pS4 

    Small cell lung cancer (SCLC) is among the most lethal solid tumor malignancies, yet treatment outcomes have remained virtually unchanged for 30 years. New treatment paradigms are sorely needed. We have developed a series of genetically engineered mouse models of SCLC, in which conditional...

  • How Has Genetic Testing Changed Treatment Approaches for Patients With Lung Cancer? Tyson, Leslie B. // ONS Connect;Feb2012, Vol. 27 Issue 2, p15 

    The author discusses the significant contribution of genetic testing in changing the treatment approaches used for lung cancer patients. She notes research results suggesting that patients with nonsquamous non-small cell lung cancer (NSCLC) have better responses to pemetrexed than those with...

  • Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer. Lee, Hyo-Sun; Lee, Yun-Gyoo; Koo, Dong-Hoe; Oh, Sukjoong; Nam, Heerim; Song, Jae-Uk; Lim, Seong; Lim, Si-young; Lee, Seung-Sei; Lim, Seong Yong // Cancer Chemotherapy & Pharmacology;Nov2015, Vol. 76 Issue 5, p933 

    Purpose: Ifosfamide, a potent alkylating agent, is rarely incorporated into small cell lung cancer (SCLC) treatment. The aim of this study was to assess the efficacy and safety of ifosfamide in combination with carboplatin and etoposide (ICE) in previously untreated patients with...

  • Effects of Local Radiation Combined with Chemotherapy in the treatment of Patients with Extensive-stage Small Cell Lung Cancer. Di WU; Jian FANG; Jun NIE; Ling DAI; Xiaoling CHEN; Jie ZHANG; Weiheng HU; Jindi HAN; Xiangjuan MA; Guangming TIAN; Sen HAN; Jieran LONG; Yang WANG // Chinese Journal of Lung Cancer;5/20/2015, Vol. 18 Issue 5, p272 

    Background and objective Chemotherapy is a highly efficient primary treatment for extensive-stage small cell lung cancer (ES-SCLC). However, patients receiving such treatment are prone to develop drug resistance. Local treatment is palliative and thus can alleviate the local symptoms and improve...

  • Radiation Therapy in the Management of Lung Cancer. Hijal, Tarek; Wan, Jonathan; Souhami, Luis // Current Respiratory Medicine Reviews;2011, Vol. 7 Issue 5, p323 

    Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer mortality worldwide. Radiation therapy (RT) plays an important role in the management of both small cell (SCLC) and non-small cell lung cancer (NSCLC), as 50 to 60% of patients diagnosed with lung cancer will...

  • Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. Rudin, Charles M.; Giaccone, Giuseppe; Ismaila, Nofisat // Journal of Oncology Practice;Jan2016, Vol. 12 Issue 1, p83 

    The article presents the American College of Chest Physicians (ACCP) Clinical Practice Guideline on the Treatment of Small-Cell Lung Cancer (SCLC) endorsed by the American Society of Clinical Oncology (ASCO), with minor qualifying statements. Topics discussed include ASCO key recommendations for...

  • Present status and upcoming prospects of hedgehog pathway inhibitors in small cell lung cancer therapy. Naqvi, Syed Hassan Abbas; Naqvi, Syed Hassan Shiraz; Bandukda, Muhammad Yasin; Naqvi, Syed Mumtaz Ali // Infectious Agents & Cancer;2013, Vol. 8 Issue 1, p17 

    Lung cancer is an important etiology of malignant mortality worldwide with global statistics indicating over 1 million deaths annually. Although there have been advances in cytotoxic chemotherapy, the prognosis after treatment still remains poor. Remarkably, recent studies on the molecular level...

  • Metastatic Polyps in the Hepatic Flexura of the Colon. Tas, Adnan; Köklü, Seyfettin; Koçak, Erdem; Biyikoğlu, İbrahim; Üstün, Hüseyin // Clinical Journal of Oncology Nursing;Dec2010, Vol. 14 Issue 6, p683 

    ONS Publishing Division Policy Regarding Letters to the Editor: Selection of letters to be published in Letters to the Editor is the decision of the editor. For acceptance, letters must be signed. A letter can appear anonymously if requested by the author. All letters are subject to editing.A...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics